← Leaderboards
Jonathan G Goldin
University Of California Los Angeles
$3,778,001
Attributed
$6,809,375
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $687.5K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,809,375 · 9
By mechanism
R01$3,456,493 · 2
M01$1,817,019 · 4
U01$1,149,151 · 1
P50$386,712 · 1
P01$0 · 1
Top collaborators
- Matthew S Brown7 shared
- Grace Hyun Jung Kim7 shared
- Michael F Mcnitt-Gray7 shared
- Frederic Noo4 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Daniel H Geschwind$113,418,228
- Michael F McNitt-Gray$11,393,331
- Donald P Tashkin$15,930,292
- Grace Hyun Jung Kim$1,270,727
- Janet Christine Frank$8,924,697
Others in their field
Top investigators on “Computed Axial Tomography”
- Eric A Hoffman · University Of Iowa$12,788,048
- John S. Werner · University Of California Davis$8,407,308
- Simon R Cherry · University Of California Los Angeles$7,960,779
- Howard N Hodis · University Of Southern California$7,910,292
- Ramsey D. Badawi · University Of California At Davis$7,775,878
- Scott Dean Metzler · Duke University$6,729,289
Research focus
Computed Axial TomographyClinical TrialsAffectImageLungProtocols DocumentationReconstructionX-Ray Computed TomographyDensityData SetHuman SubjectBioimaging /Biomedical ImagingQuantitative ImagingDiagnosis Design /EvaluationClinical ResearchBiological MarkersCause Of DeathAccountingDevicesEligibility DeterminationCollaborationsEffectivenessFda ApprovedClinical Translation
Grant awards (19)
Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection$668,617
R01 · FY2024 · HL
Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection$682,261
R01 · FY2023 · HL
Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection$673,505
R01 · FY2022 · HL
Robust Clinical Translation of CT Imaging Biomarker in COPD for EBV Patient Selection$687,505
R01 · FY2021 · HL
Quantitative CT Imaging for Response Assessment when using Dose Reduction Methods$393,868
U01 · FY2016 · CA
Quantitative CT Imaging for Response Assessment when using Dose Reduction Methods$374,661
U01 · FY2015 · CA
Quantitative CT Imaging for Response Assessment when using Dose Reduction Methods$380,622
U01 · FY2014 · CA
CONTEMPORARY SCREENING FOR THE DETECTION OF LUNG CANCER$122,608
M01 · FY2007 · RR · contact PI
CONTEMPORARY SCREENING FOR THE DETECTION OF LUNG CANCER$495,812
M01 · FY2006 · RR · contact PI
CONTEMPORARY SCREENING FOR THE DETECTION OF LUNG CANCER$429,067
M01 · FY2005 · RR
Quantative image analysis models of IPF pathogenesis$204,345
P50 · FY2005 · HL
Contemporary Screening for the Detection of Lung Cancer$355,000
M01 · FY2004 · RR
Alveolitis and Fibrosis in Scleroderma Lung Disease$246,403
R01 · FY2004 · HL
Alveolitis and Fibrosis in Scleroderma Lung Disease$249,101
R01 · FY2003 · HL
Alveolitis and Fibrosis in Scleroderma Lung Disease$249,101
R01 · FY2002 · HL
Quantative image analysis models of IPF pathogenesis$182,367
P50 · FY2002 · HL
EXTENT &SIGNIFICANCE OF CORONARY ARTERY CALCIFICATION$207,266
M01 · FY2001 · RR
EXTENT &SIGNIFICANCE OF CORONARY ARTERY CALCIFICATION$207,266
M01 · FY2001 · RR
Quantative image analysis models of IPF pathogenesis$0
P01 · FY2001 · HL